Trial Profile
To evaluate the efficacy of intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia with/without dome shaped macula
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 28 Feb 2018 New trial record